Eldad Melamed - Publications

Affiliations: 
Tel Aviv University, Tel Aviv-Yafo, Tel Aviv District, Israel 

159 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. Jama Neurology. 1-8. PMID 26751635 DOI: 10.1001/jamaneurol.2015.4321  0.56
2014 Lamm O, Ganz J, Melamed E, Offen D. Harnessing neurogenesis for the possible treatment of Parkinson's disease. The Journal of Comparative Neurology. 522: 2817-30. PMID 24723264 DOI: 10.1002/cne.23607  0.56
2014 Petrou P, Argov A, Lennon VA, Gotkine M, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D. Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy. Muscle & Nerve. 49: 455-7. PMID 24327321 DOI: 10.1002/mus.24143  0.56
2014 de Munter JP, Melamed E, Wolters ECh. Stem cell grafting in parkinsonism--why, how and when. Parkinsonism & Related Disorders. 20: S150-3. PMID 24262169 DOI: 10.1016/S1353-8020(13)70036-1  0.56
2014 Benninger F, Khlebtovsky A, Roditi Y, Keret O, Steiner I, Melamed E, Djaldetti R. Beneficial effect of levodopa therapy on stooped posture in Parkinson's disease Gait and Posture. DOI: 10.1016/j.gaitpost.2015.05.015  0.56
2013 Melamed E. The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1912-4. PMID 24307480 DOI: 10.1002/mds.25728  0.56
2013 Greenbaum L, Lorberboym M, Melamed E, Rigbi A, Barhum Y, Kohn Y, Khlebtovsky A, Lerer B, Djaldetti R. Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Frontiers in Neuroscience. 7: 52. PMID 23596382 DOI: 10.3389/fnins.2013.00052  0.56
2013 Lev N, Barhum Y, Ben-Zur T, Melamed E, Steiner I, Offen D. Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity. Journal of Molecular Neuroscience : Mn. 50: 542-50. PMID 23536331 DOI: 10.1007/s12031-013-9984-9  0.56
2013 Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Köllensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, ... ... Melamed E, et al. The natural history of multiple system atrophy: a prospective European cohort study. The Lancet. Neurology. 12: 264-74. PMID 23391524 DOI: 10.1016/S1474-4422(12)70327-7  0.56
2013 Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 86-95. PMID 22927060 DOI: 10.1002/mds.24997  0.56
2013 Lev N, Barhum Y, Pilosof NS, Ickowicz D, Cohen HY, Melamed E, Offen D. DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 68: 215-25. PMID 22887838 DOI: 10.1093/gerona/gls147  0.56
2012 Dadon-Nachum M, Ben-Zur T, Srugo I, Shamir HM, Melamed E, Yaffe D, Offen D. Therapeutic effect of myogenic cells modified to express neurotrophic factors in a rat model of sciatic nerve injury. Journal of Stem Cells & Regenerative Medicine. 8: 21-7. PMID 24693189  0.56
2012 Sadan O, Melamed E, Offen D. Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease. Plos Currents. 4: e4f7f6dc013d4e. PMID 22953237 DOI: 10.1371/4f7f6dc013d4e  0.56
2012 Shruster A, Ben-Zur T, Melamed E, Offen D. Wnt signaling enhances neurogenesis and improves neurological function after focal ischemic injury. Plos One. 7: e40843. PMID 22815838 DOI: 10.1371/journal.pone.0040843  0.56
2012 Fisher-Shoval Y, Barhum Y, Sadan O, Yust-Katz S, Ben-Zur T, Lev N, Benkler C, Hod M, Melamed E, Offen D. Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. Journal of Molecular Neuroscience : Mn. 48: 176-84. PMID 22638856 DOI: 10.1007/s12031-012-9805-6  0.56
2012 Greenbaum L, Tegeder I, Barhum Y, Melamed E, Roditi Y, Djaldetti R. Contribution of genetic variants to pain susceptibility in Parkinson disease. European Journal of Pain (London, England). 16: 1243-50. PMID 22473870 DOI: 10.1002/j.1532-2149.2012.00134.x  0.56
2012 Khlebtovsky A, Rigbi A, Melamed E, Ziv I, Steiner I, Gad A, Djaldetti R. Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias. Journal of Neural Transmission (Vienna, Austria : 1996). 119: 1367-71. PMID 22437202 DOI: 10.1007/s00702-012-0796-9  0.56
2012 Sadan O, Shemesh N, Barzilay R, Dadon-Nahum M, Blumenfeld-Katzir T, Assaf Y, Yeshurun M, Djaldetti R, Cohen Y, Melamed E, Offen D. Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease. Experimental Neurology. 234: 417-27. PMID 22285250 DOI: 10.1016/j.expneurol.2011.12.045  0.56
2012 Melamed E, Poewe W. Taking sides: is handedness involved in motor asymmetry of Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 27: 171-3. PMID 22223083 DOI: 10.1002/mds.24048  0.56
2012 Yust-Katz S, Fisher-Shoval Y, Barhum Y, Ben-Zur T, Barzilay R, Lev N, Hod M, Melamed E, Offen D. Placental mesenchymal stromal cells induced into neurotrophic factor-producing cells protect neuronal cells from hypoxia and oxidative stress. Cytotherapy. 14: 45-55. PMID 22040110 DOI: 10.3109/14653249.2011.613928  0.56
2012 Yust-Katz S, Shitrit D, Melamed E, Djaldetti R. Respiratory distress: an unrecognized non-motor phenomenon in patients with parkinsonism. Journal of Neural Transmission (Vienna, Austria : 1996). 119: 73-6. PMID 21706303 DOI: 10.1007/s00702-011-0671-0  0.56
2011 Barzilay R, Ben-Zur T, Sadan O, Bren Z, Taler M, Lev N, Tarasenko I, Uzan R, Gil-Ad I, Melamed E, Weizman A, Offen D. Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice. Translational Psychiatry. 1: e61. PMID 22832353 DOI: 10.1038/tp.2011.64  0.56
2011 Dadon-Nachum M, Melamed E, Offen D. Stem cells treatment for sciatic nerve injury. Expert Opinion On Biological Therapy. 11: 1591-7. PMID 21995439 DOI: 10.1517/14712598.2011.628933  0.56
2011 Ganz J, Lev N, Melamed E, Offen D. Cell replacement therapy for Parkinson's disease: how close are we to the clinic? Expert Review of Neurotherapeutics. 11: 1325-39. PMID 21864078 DOI: 10.1586/ern.11.74  0.56
2011 Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, ... ... Melamed E, et al. VPS35 mutations in Parkinson disease. American Journal of Human Genetics. 89: 162-7. PMID 21763482 DOI: 10.1016/j.ajhg.2011.07.018  0.56
2011 Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. The Lancet. Neurology. 10: 415-23. PMID 21482191 DOI: 10.1016/S1474-4422(11)70073-4  0.56
2011 Dadon-Nachum M, Sadan O, Srugo I, Melamed E, Offen D. Differentiated mesenchymal stem cells for sciatic nerve injury. Stem Cell Reviews. 7: 664-71. PMID 21327572 DOI: 10.1007/s12015-010-9227-1  0.56
2011 Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Cohen O, Trau H, Aharon-Peretz J, Milo R, Schwartz M, Huberman M, Gilead L, Barchana M, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 118: 1199-207. PMID 21298300 DOI: 10.1007/s00702-011-0580-2  0.56
2011 Shruster A, Eldar-Finkelman H, Melamed E, Offen D. Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid β-peptide. Journal of Neurochemistry. 116: 522-9. PMID 21138436 DOI: 10.1111/j.1471-4159.2010.07131.x  0.56
2011 Dadon-Nachum M, Melamed E, Offen D. The "dying-back" phenomenon of motor neurons in ALS. Journal of Molecular Neuroscience : Mn. 43: 470-7. PMID 21057983 DOI: 10.1007/s12031-010-9467-1  0.56
2011 Djaldetti R, Lorberboym M, Karmon Y, Treves TA, Ziv I, Melamed E. Residual striatal dopaminergic nerve terminals in very long-standing Parkinson's disease: a single photon emission computed tomography imaging study. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 327-30. PMID 20939078 DOI: 10.1002/mds.23380  0.56
2011 Kan I, Barhum Y, Melamed E, Offen D. Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice. Stem Cell Reviews. 7: 404-12. PMID 20830611 DOI: 10.1007/s12015-010-9190-x  0.56
2010 Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim MB, Weinreb O. Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application. The Epma Journal. 1: 343-61. PMID 23199069 DOI: 10.1007/s13167-010-0026-1  0.56
2010 Levkovitch-Verbin H, Sadan O, Vander S, Rosner M, Barhum Y, Melamed E, Offen D, Melamed S. Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection. Investigative Ophthalmology & Visual Science. 51: 6394-400. PMID 20926814 DOI: 10.1167/iovs.09-4310  0.56
2010 Ziv I, Melamed E. Editorial: apoptosis in the aging brain. Apoptosis : An International Journal On Programmed Cell Death. 15: 1285-91. PMID 20821350 DOI: 10.1007/s10495-010-0536-2  0.56
2010 Aharoni S, Traves TA, Melamed E, Cohen S, Silver EL. MELAS syndrome associated with both A3243G-tRNALeu mutation and multiple mitochondrial DNA deletions. Journal of the Neurological Sciences. 296: 101-3. PMID 20655066 DOI: 10.1016/j.jns.2010.06.029  0.56
2010 Shruster A, Melamed E, Offen D. Neurogenesis in the aged and neurodegenerative brain. Apoptosis : An International Journal On Programmed Cell Death. 15: 1415-21. PMID 20339917 DOI: 10.1007/s10495-010-0491-y  0.56
2010 Hellmann MA, Melamed E, Steinmetz AP, Djaldetti R. Unilateral lower limb rest tremor is not necessarily a presenting symptom of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 924-7. PMID 20198647 DOI: 10.1002/mds.23030  0.56
2010 Shemesh N, Sadan O, Melamed E, Offen D, Cohen Y. Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels. Nmr in Biomedicine. 23: 196-206. PMID 19950122 DOI: 10.1002/nbm.1443  0.56
2010 Barhum Y, Gai-Castro S, Bahat-Stromza M, Barzilay R, Melamed E, Offen D. Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. Journal of Molecular Neuroscience : Mn. 41: 129-37. PMID 19902385 DOI: 10.1007/s12031-009-9302-8  0.56
2009 Sadan O, Melamed E, Offen D. Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opinion On Biological Therapy. 9: 1487-97. PMID 19821796 DOI: 10.1517/14712590903321439  0.56
2009 Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. The New England Journal of Medicine. 361: 1268-78. PMID 19776408 DOI: 10.1056/NEJMoa0809335  0.56
2009 Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D. Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. The Israel Medical Association Journal : Imaj. 11: 201-4. PMID 19603590  0.56
2009 Barzilay R, Melamed E, Offen D. Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. Stem Cells (Dayton, Ohio). 27: 2509-15. PMID 19591229 DOI: 10.1002/stem.172  0.56
2009 Barzilay R, Sadan O, Melamed E, Offen D. Comparative characterization of bone marrow-derived mesenchymal stromal cells from four different rat strains. Cytotherapy. 11: 435-42. PMID 19521891 DOI: 10.1080/14653240902849796  0.56
2009 Djaldetti R, Treves TA, Ziv I, Melamed E, Lampl Y, Lorberboym M. Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 30: 301-5. PMID 19499179 DOI: 10.1007/s10072-009-0100-4  0.56
2009 Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D. Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells. Stem Cells and Development. 18: 591-601. PMID 19298173 DOI: 10.1089/scd.2008.0138  0.56
2009 Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, Cohen Y, Melamed E, Offen D. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells and Development. 18: 1179-90. PMID 19243240 DOI: 10.1089/scd.2008.0411  0.56
2009 Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 793-800. PMID 19224610 DOI: 10.1002/mds.22172  0.56
2009 Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe WH, Stocchi F, Tolosa E. Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 655-61. PMID 19127595 DOI: 10.1002/mds.21745  0.56
2009 Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. Journal of Molecular Neuroscience : Mn. 39: 199-210. PMID 19127447 DOI: 10.1007/s12031-008-9166-3  0.56
2009 Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D. DJ-1 protects against dopamine toxicity. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 151-60. PMID 18974921 DOI: 10.1007/s00702-008-0134-4  0.56
2009 Lev N, Ickowicz D, Barhum Y, Melamed E, Offen D. DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS. Journal of Molecular Neuroscience : Mn. 38: 94-102. PMID 18712292 DOI: 10.1007/s12031-008-9138-7  0.56
2009 Offen D, Barhum Y, Melamed E, Embacher N, Schindler C, Ransmayr G. Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant. Journal of Molecular Neuroscience : Mn. 38: 85-93. PMID 18651250 DOI: 10.1007/s12031-007-9004-z  0.56
2009 Gershanik OS. Case Study 21 Parkinsonian Disorders in Clinical Practice. 167-170. DOI: 10.1002/9781444306385.ch3  0.56
2009 Melamed E, Offen D, Blondheim-Shraga NR, Kan I. Stem cell therapies for the treatment of neurodegenerative disease Innovations in Pharmaceutical Technology. 48-50.  0.56
2008 Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 2194-201. PMID 18932271 DOI: 10.1002/mds.22218  0.56
2008 Djaldetti R, Hassin-Baer S, Farrer MJ, Vilariño-Güell C, Ross OA, Kolianov V, Yust-Katz S, Treves TA, Barhum Y, Hulihan M, Melamed E. Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 1279-84. PMID 18665323 DOI: 10.1007/s00702-008-0074-z  0.56
2008 Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, Offen D. Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells (Dayton, Ohio). 26: 2542-51. PMID 18635865 DOI: 10.1634/stemcells.2008-0240  0.56
2008 Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy. 10: 340-52. PMID 18574767 DOI: 10.1080/14653240802021330  0.56
2008 Funayama M, Li Y, Tsoi TH, Lam CW, Ohi T, Yazawa S, Uyama E, Djaldetti R, Melamed E, Yoshino H, Imamichi Y, Takashima H, Nishioka K, Sato K, Tomiyama H, et al. Familial Parkinsonism with digenic parkin and PINK1 mutations. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1461-5. PMID 18546294 DOI: 10.1002/mds.22143  0.56
2008 Barzilay R, Kan I, Ben-Zur T, Bulvik S, Melamed E, Offen D. Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells and Development. 17: 547-54. PMID 18513164 DOI: 10.1089/scd.2007.0172  0.56
2008 Lev N, Ickowicz D, Melamed E, Offen D. Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology. 29: 397-405. PMID 18377993 DOI: 10.1016/j.neuro.2008.01.007  0.56
2008 Yust-Katz S, Tesler D, Treves TA, Melamed E, Djaldetti R. Handedness as a predictor of side of onset of Parkinson's disease. Parkinsonism & Related Disorders. 14: 633-5. PMID 18346926 DOI: 10.1016/j.parkreldis.2008.01.017  0.56
2008 Yust-Katz S, Sthneer S, Melamed E, Djaldetti R. Long-term Parkinson's disease--time for optimism. Biomedicine & Pharmacotherapy = BioméDecine & PharmacothéRapie. 62: 233-5. PMID 18294809 DOI: 10.1016/j.biopha.2007.12.014  0.56
2008 Djaldetti R, Nageris BI, Lorberboym M, Treves TA, Melamed E, Yaniv E. [(123)I]-FP-CIT SPECT and olfaction test in patients with combined postural and rest tremor. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 469-72. PMID 18250955 DOI: 10.1007/s00702-007-0851-0  0.56
2008 Hellmann MA, Sabach T, Melamed E, Djaldetti R. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease. Biomedicine & Pharmacotherapy = BioméDecine & PharmacothéRapie. 62: 250-2. PMID 17967525 DOI: 10.1016/j.biopha.2007.09.002  0.56
2007 Lev N, Melamed E, Offen D. Toxic causes of parkinsonism. Handbook of Clinical Neurology. 84: 385-98. PMID 18808959 DOI: 10.1016/S0072-9752(07)84050-4  0.56
2007 Djaldetti R, Melamed E. Sensory symptoms in Parkinson's disease. Handbook of Clinical Neurology. 83: 377-84. PMID 18808923 DOI: 10.1016/S0072-9752(07)83016-8  0.56
2007 Melamed E, Ziv I, Djaldetti R. Management of motor complications in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 22: S379-84. PMID 18175400 DOI: 10.1002/mds.21680  0.56
2007 Djaldetti R, Treves TA, Ziv I, Melamed E, Lorberboym M. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with recurrent sudden falls: are such falls a distinct entity? Journal of Nuclear Medicine Technology. 35: 232-6. PMID 18006592 DOI: 10.2967/jnmt.107.040238  0.56
2007 Offen D, Barhum Y, Levy YS, Burshtein A, Panet H, Cherlow T, Melamed E. Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease. Journal of Neural Transmission. Supplementum. 133-43. PMID 17982886 DOI: 10.1007/978-3-211-73574-9-16  0.56
2007 Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clinical Neuropharmacology. 30: 201-5. PMID 17762316 DOI: 10.1097/wnf.0b013e3180340319  0.56
2007 Kan I, Melamed E, Offen D. Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases. Handbook of Experimental Pharmacology. 219-42. PMID 17554511 DOI: 10.1007/978-3-540-68976-8_10  0.56
2007 Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, ... ... Melamed E, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. Journal of Neuropathology and Experimental Neurology. 66: 329-36. PMID 17483689 DOI: 10.1097/nen.0b013e318053716a  0.56
2007 Kan I, Ben-Zur T, Barhum Y, Levy YS, Burstein A, Charlow T, Bulvik S, Melamed E, Offen D. Dopaminergic differentiation of human mesenchymal stem cells--utilization of bioassay for tyrosine hydroxylase expression. Neuroscience Letters. 419: 28-33. PMID 17475405 DOI: 10.1016/j.neulet.2007.03.070  0.56
2007 Abraham A, Elena C, Melamed E, Djaldetti R. Successful treatment of truncal myoclonus. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1055-6. PMID 17427937 DOI: 10.1002/mds.21469  0.56
2007 Litvan I, Halliday G, Hallett M, Goetz CG, Rocca W, Duyckaerts C, Ben-Shlomo Y, Dickson DW, Lang AE, Chesselet MF, Langston WJ, Di Monte DA, Gasser T, Hagg T, Hardy J, ... ... Melamed E, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. Journal of Neuropathology and Experimental Neurology. 66: 251-7. PMID 17413315 DOI: 10.1097/nen.0b013e3180415e42  0.56
2007 Reshef A, Shirvan A, Grimberg H, Levin G, Cohen A, Mayk A, Kidron D, Djaldetti R, Melamed E, Ziv I. Novel molecular imaging of cell death in experimental cerebral stroke. Brain Research. 1144: 156-64. PMID 17328873 DOI: 10.1016/j.brainres.2007.01.095  0.56
2007 Kan I, Melamed E, Offen D, Green P. Docosahexaenoic acid and arachidonic acid are fundamental supplements for the induction of neuronal differentiation. Journal of Lipid Research. 48: 513-7. PMID 17185746 DOI: 10.1194/jlr.C600022-JLR200  0.56
2007 Grunfeld JF, Barhum Y, Blondheim N, Rabey JM, Melamed E, Offen D. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Experimental Neurology. 204: 260-3. PMID 17174305 DOI: 10.1016/j.expneurol.2006.11.002  0.56
2007 Lev N, Gilgun-Sherki Y, Offen D, Melamed E. The role of oxidative stress in the pathogenesis of multiple sclerosis: Current state Oxidative Stress and Neurodegenerative Disorders. 283-295. DOI: 10.1016/B978-044452809-4/50154-X  0.56
2007 Zigelboim I, Offen D, Melamed E, Panet H, Rehavi M, Cohen Y. Synthesis, binding affinity, and relaxivity of target-specific MRI contrast agents Journal of Inclusion Phenomena and Macrocyclic Chemistry. 59: 323-329. DOI: 10.1007/s10847-007-9331-2  0.56
2007 Lev N, Djaldetti R, Melamed E. Initiation of symptomatic therapy in Parkinson's disease: Dopamine agonists versus levodopa Journal of Neurology. 254: 19-26. DOI: 10.1007/s00415-007-5004-8  0.56
2006 Djaldetti R, Lorberboym M, Melamed E. Primary postural instability: a cause of recurrent sudden falls in the elderly. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 27: 412-6. PMID 17205226 DOI: 10.1007/s10072-006-0720-x  0.56
2006 Melamed E, Djaldetti R. Camptocormia in Parkinson's disease. Journal of Neurology. 253: VII14-16. PMID 17131221 DOI: 10.1007/s00415-006-7004-5  0.56
2006 Lev N, Roncevic D, Roncevich D, Ickowicz D, Melamed E, Offen D. Role of DJ-1 in Parkinson's disease. Journal of Molecular Neuroscience : Mn. 29: 215-25. PMID 17085780 DOI: 10.1385/JMN:29:3:215  0.56
2006 Djaldetti R, Melamed E. Camptocormia in Parkinson's disease: new insights. Journal of Neurology, Neurosurgery, and Psychiatry. 77: 1205. PMID 17043289 DOI: 10.1136/jnnp.2006.099184  0.56
2006 Lev N, Ickowicz D, Barhum Y, Blondheim N, Melamed E, Offen D. Experimental encephalomyelitis induces changes in DJ-1: implications for oxidative stress in multiple sclerosis. Antioxidants & Redox Signaling. 8: 1987-95. PMID 17034344 DOI: 10.1089/ars.2006.8.1987  0.56
2006 Gilgun-Sherki Y, Melamed E, Offen D. Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. Current Pharmaceutical Design. 12: 3509-19. PMID 17017944 DOI: 10.2174/138161206778343091  0.56
2006 Hellmann MA, Djaldetti R, Israel Z, Melamed E. Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 2008-10. PMID 16972244 DOI: 10.1002/mds.21090  0.56
2006 Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson's disease. The Lancet. Neurology. 5: 796-802. PMID 16914408 DOI: 10.1016/S1474-4422(06)70549-X  0.56
2006 Dabby R, Djaldetti R, Shahmurov M, Treves TA, Gabai B, Melamed E, Sadeh M, Avinoach I. Skin biopsy for assessment of autonomic denervation in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 113: 1169-76. PMID 16835698 DOI: 10.1007/s00702-005-0431-0  0.56
2006 Oved D, Ziv I, Treves TA, Paleacu D, Melamed E, Djaldetti R. Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1257-61. PMID 16685690 DOI: 10.1002/mds.20929  0.56
2006 Blondheim NR, Levy YS, Ben-Zur T, Burshtein A, Cherlow T, Kan I, Barzilai R, Bahat-Stromza M, Barhum Y, Bulvik S, Melamed E, Offen D. Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells and Development. 15: 141-64. PMID 16646662 DOI: 10.1089/scd.2006.15.141  0.56
2006 Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T, Lu CS, Inzelberg R, Djaldetti R, Melamed E, Amouri R, Gouider-Khouja N, Hentati F, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1102-8. PMID 16622854 DOI: 10.1002/mds.20886  0.56
2006 Lev N, Melamed E, Offen D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neuroscience Letters. 399: 27-32. PMID 16584840 DOI: 10.1016/j.neulet.2005.09.086  0.56
2006 Barzilay R, Levy YS, Melamed E, Offen D. Adult stem cells for neuronal repair. The Israel Medical Association Journal : Imaj. 8: 61-6. PMID 16450758  0.56
2006 Tanne D, Goldbourt U, Koton S, Grossman E, Koren-Morag N, Green MS, Bornstein NM, Behar S, Sandach A, Schwartz R, Benderly M, Tsabari R, Rabey JM, Kimiagar I, Shevtsov E, ... ... Melamed E, et al. A national survey of acute cerebrovascular disease in Israel: Burden, management, outcome and adherence to guidelines Israel Medical Association Journal. 8: 3-7. PMID 16450742  0.56
2006 Hellmann MA, Panet H, Barhum Y, Melamed E, Offen D. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neuroscience Letters. 395: 124-8. PMID 16359791 DOI: 10.1016/j.neulet.2005.10.097  0.56
2006 Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 510-4. PMID 16250023 DOI: 10.1002/mds.20748  0.56
2005 Sadan O, Bahat-Stromza M, Gilgun-Sherki Y, Atlas D, Melamed E, Offen D. A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia. Clinical Neuropharmacology. 28: 285-8. PMID 16340385 DOI: 10.1097/01.wnf.0000191331.54649.e3  0.56
2005 Gilgun-Sherki Y, Barhum Y, Atlas D, Melamed E, Offen D. Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant. Journal of Molecular Neuroscience : Mn. 27: 125-35. PMID 16055951 DOI: 10.1385/JMN:27:1:125  0.56
2005 Levy YS, Gilgun-Sherki Y, Melamed E, Offen D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 19: 97-127. PMID 15807629 DOI: 10.2165/00063030-200519020-00003  0.56
2005 Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 365: 947-54. PMID 15766996 DOI: 10.1016/S0140-6736(05)71083-7  0.56
2005 Bahat-Stroomza M, Gilgun-Sherki Y, Offen D, Panet H, Saada A, Krool-Galron N, Barzilai A, Atlas D, Melamed E. A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. The European Journal of Neuroscience. 21: 637-46. PMID 15733082 DOI: 10.1111/j.1460-9568.2005.03889.x  0.56
2005 Kan I, Melamed E, Offen D. Integral therapeutic potential of bone marrow mesenchymal stem cells. Current Drug Targets. 6: 31-41. PMID 15720211 DOI: 10.2174/1389450053344902  0.56
2004 Elkon H, Melamed E, Offen D. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. Journal of Molecular Neuroscience : Mn. 24: 387-400. PMID 15655261 DOI: 10.1385/JMN:24:3:387  0.56
2004 Levy YS, Stroomza M, Melamed E, Offen D. Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease. Journal of Molecular Neuroscience : Mn. 24: 353-86. PMID 15655260 DOI: 10.1385/JMN:24:3:353  0.56
2004 Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 45: 1688-93. PMID 15471834  0.56
2004 Djaldetti R, Hellmann M, Melamed E. Bent knees and tiptoeing: late manifestations of end-stage Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 1325-8. PMID 15389997 DOI: 10.1002/mds.20187  0.56
2004 Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, ... ... Melamed E, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 997-1005. PMID 15372588 DOI: 10.1002/mds.20519  0.56
2004 Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. The Pharmacogenomics Journal. 4: 291-306. PMID 15224083 DOI: 10.1038/sj.tpj.6500260  0.56
2004 Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 62: 2171-5. PMID 15210877  0.56
2004 Offen D, Gilgun-Sherki Y, Barhum Y, Benhar M, Grinberg L, Reich R, Melamed E, Atlas D. A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. Journal of Neurochemistry. 89: 1241-51. PMID 15147517 DOI: 10.1111/j.1471-4159.2004.02428.x  0.56
2004 Lev N, Barhum Y, Melamed E, Offen D. Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice. Neuroscience Letters. 359: 139-42. PMID 15050683 DOI: 10.1016/j.neulet.2004.01.076  0.56
2004 Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. Journal of Neurology. 251: 261-8. PMID 15015004 DOI: 10.1007/s00415-004-0348-9  0.56
2004 Streifler JY, Israel D, Melamed E. The hyperperfusion syndrome: an under-recognized complication of carotid endarterectomy. The Israel Medical Association Journal : Imaj. 6: 54-6. PMID 14740513  0.56
2004 Gilgun-Sherki Y, Hellmann M, Melamed E, Offen D. The role of neurotransmitters and neuropeptides in Parkinson's disease: Implications for therapy Drugs of the Future. 29: 1261-1272. DOI: 10.1358/dof.2004.029.12.869227  0.56
2003 Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clinical Neuropharmacology. 26: 322-6. PMID 14646613 DOI: 10.1097/00002826-200311000-00012  0.56
2003 Levy YS, Merims D, Panet H, Barhum Y, Melamed E, Offen D. Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells. Journal of Molecular Neuroscience : Mn. 21: 121-32. PMID 14593212 DOI: 10.1385/JMN:21:2:121  0.56
2003 Gilgun-Sherki Y, Panet H, Melamed E, Offen D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Research. 989: 196-204. PMID 14556941 DOI: 10.1016/S0006-8993(03)03343-2  0.56
2003 Gilgun-Sherki Y, Melamed E, Offen D. Antioxidant treatment in Alzheimer's disease: current state. Journal of Molecular Neuroscience : Mn. 21: 1-11. PMID 14500988 DOI: 10.1385/JMN:21:1:1  0.56
2003 Djaldetti R, Lev N, Melamed E. Neuroprotection in progressive brain disorders. The Israel Medical Association Journal : Imaj. 5: 576-80. PMID 12929297  0.56
2003 Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacology & Toxicology. 93: 66-70. PMID 12899667 DOI: 10.1034/j.1600-0773.2003.930202.x  0.56
2003 Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clinical Neuropharmacology. 26: 196-8. PMID 12897640 DOI: 10.1097/00002826-200307000-00009  0.56
2003 Gilgun-Sherki Y, Melamed E, Ziv I, Offen D. Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacology & Toxicology. 93: 54-6. PMID 12828575 DOI: 10.1034/j.1600-0773.2003.930108.x  0.56
2002 Shirvan A, Kimron M, Holdengreber V, Ziv I, Ben-Shaul Y, Melamed S, Melamed E, Barzilai A, Solomon AS. Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy. The Journal of Biological Chemistry. 277: 49799-807. PMID 12376549 DOI: 10.1074/jbc.M204793200  0.56
2000 Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clinical Neuropharmacology. 23: 324-30. PMID 11575866 DOI: 10.1097/00002826-200011000-00005  0.56
2000 Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Research. 854: 257-62. PMID 10784133 DOI: 10.1016/S0006-8993(99)02375-6  0.56
2000 Hochman A, Liang H, Offen D, Melamed E, Sternin H. Developmental changes in antioxidant enzymes and oxidative damage in kidneys, liver and brain of bcl-2 knockout mice. Cellular and Molecular Biology (Noisy-Le-Grand, France). 46: 41-52. PMID 10726970  0.56
1999 Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, ... ... Melamed E, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 911-3. PMID 10584663 DOI: 10.1002/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H  0.56
1999 Offen D, Hochman A, Gorodin S, Ziv I, Shirvan A, Barzilai A, Melamed E. Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. Advances in Neurology. 80: 265-9. PMID 10410731  0.56
1999 Daily D, Barzilai A, Offen D, Kamsler A, Melamed E, Ziv I. The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53. Cellular and Molecular Neurobiology. 19: 261-76. PMID 10081609 DOI: 10.1023/A:1006933312401  0.56
1998 Hochman A, Sternin H, Gorodin S, Korsmeyer S, Ziv I, Melamed E, Offen D. Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice. Journal of Neurochemistry. 71: 741-8. PMID 9681465  0.56
1998 Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 95: 5789-94. PMID 9576963 DOI: 10.1073/pnas.95.10.5789  0.56
1997 Offen D, Ziv I, Barzilai A, Gorodin S, Glater E, Hochman A, Melamed E. Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease. Neurochemistry International. 31: 207-16. PMID 9220453 DOI: 10.1016/S0197-0186(96)00150-7  0.56
1996 Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Experimental Neurology. 141: 32-9. PMID 8797665 DOI: 10.1006/exnr.1996.0136  0.56
1995 Nerurkar VR, Achiron A, Song KJ, Melland RR, Pinhas-Hamiel O, Melamed E, Shohat B, Yanagihara R. Human T-cell lymphotropic virus type I in Iranian-born Mashhadi Jews: genetic and phylogenetic evidence for common source of infection. Journal of Medical Virology. 45: 361-6. PMID 7666039  0.56
1994 Tanner CM, Melamed E, Lees AJ. Managing motor fluctuations, dyskinesias, and other adverse effects in Parkinson's disease. Neurology. 44: S12-6. PMID 8121576  0.56
1994 Achiron A, Gilad R, Margalit R, Gabbay U, Sarova-Pinhas I, Cohen IR, Melamed E, Lider O, Noy S, Ziv I. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. Journal of Neurology, Neurosurgery, and Psychiatry. 57: 57-61. PMID 7964856 DOI: 10.1136/jnnp.57.Suppl.57  0.56
1993 Achiron A, Pinhas-Hamiel O, Doll L, Djaldetti R, Chen A, Ziv I, Avni A, Frankel G, Melamed E, Shohat B. Spastic paraparesis associated with human T-lymphotropic virus type I: a clinical, serological, and genomic study in Iranian-born Mashhadi Jews. Annals of Neurology. 34: 670-5. PMID 8239561 DOI: 10.1002/ana.410340508  0.56
1992 Achiron A, Pras E, Gilad R, Ziv I, Mandel M, Gordon CR, Noy S, Sarova-Pinhas I, Melamed E. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Archives of Neurology. 49: 1233-6. PMID 1449400 DOI: 10.1001/archneur.1992.00530360031013  0.56
1982 Growdon JH, Melamed E, Logue M, Hefti F, Wurtman RJ. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life Sciences. 30: 827-32. PMID 6175872  1
1982 Melamed E, Hefti F, Wurtman RJ. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model. Israel Journal of Medical Sciences. 18: 159-63. PMID 6121770  1
1981 Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. The Journal of Pharmacology and Experimental Therapeutics. 217: 189-97. PMID 7205652  1
1981 Melamed E, Hefti F, Pettibone DJ, Liebman J, Wurtman RJ. Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Neurology. 31: 651-5. PMID 7195482  0.56
1980 Melamed E, Hefti F, Wurtman RJ. Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries. Brain Research. 198: 244-8. PMID 7407592  1
1980 Melamed E, Hefti F, Wurtman RJ. Diminished decarboxylation of L-DOPA in rat striatum after intrastriatal injections of kainic acid. Neuropharmacology. 19: 409-11. PMID 7383284  1
1980 Melamed E, Hefti F, Wurtman RJ. L-3,4-Dihydroxyphenylalanine and L-5-hydroxytryptophan decarboxylase activities in rat striatum: effect of selective destruction of dopaminergic or serotoninergic input. Journal of Neurochemistry. 34: 1753-6. PMID 7381499  1
1980 Melamed E, Glaeser B, Growdon JH, Wurtman RJ. Plasma tyrosine in normal humans: effects of oral tyrosine and protein-containing meals. Journal of Neural Transmission. 47: 299-306. PMID 7190187  1
1980 Hefti F, Melamed E, Sahakian BJ, Wurtman RJ. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacology, Biochemistry, and Behavior. 12: 185-8. PMID 7189592  1
1980 Hefti F, Melamed E, Wurtman RJ. The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model. Journal of Neural Transmission. Supplementum. 95-101. PMID 6776238  1
1980 Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Annals of Neurology. 8: 558-63. PMID 6260009 DOI: 10.1002/ana.410080603  1
1980 Melamed E, Hefti F, Wurtman RJ. Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions. Proceedings of the National Academy of Sciences of the United States of America. 77: 4305-9. PMID 6254020  1
1980 Wurtman RJ, Hefti F, Melamed E. Precursor control of neurotransmitter synthesis. Pharmacological Reviews. 32: 315-35. PMID 6115400  1
1980 Hefti F, Melamed E, Wurtman RJ. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Research. 195: 123-37. PMID 6105003  1
1980 Melamed E, Hefti F, Liebman J, Schlosberg AJ, Wurtman RJ. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease. Nature. 283: 772-4. PMID 6101905  1
1979 Glaeser BS, Melamed E, Growdon JH, Wurtman RJ. Elevation of plasma tyrosine after a single oral dose of L-tyrosine. Life Sciences. 25: 265-71. PMID 481129  1
Show low-probability matches.